Phosphoric acid

Identification

Name
Phosphoric acid
Accession Number
DB09394
Type
Small Molecule
Groups
Approved
Description

Phosphoric Acid is a colorless, odorless phosphorus-containing inorganic acid. Phosphoric acid is a sequestering agent which binds many divalent cations, including Fe++, Cu++, Ca++, and Mg++.

Structure
Thumb
Synonyms
Not Available
External IDs
E 338 / E-338 / FEMA NO. 2900 / INS NO.338 / INS-338 / NSC-80804 / Y-11A06
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AminosynPhosphoric acid (40 mg/100mL) + Glycine (448 mg/100mL) + Histidine (105 mg/100mL) + L-Alanine (448 mg/100mL) + L-Arginine (343 mg/100mL) + L-Isoleucine (252 mg/100mL) + L-Leucine (329 mg/100mL) + L-Lysine acetate (252 mg/100mL) + L-Phenylalanine (154 mg/100mL) + L-Proline (300 mg/100mL) + L-Threonine (182 mg/100mL) + L-Tryptophan (56 mg/100mL) + L-Tyrosine (31 mg/100mL) + L-Valine (280 mg/100mL) + Magnesium acetate (21 mg/100mL) + Methionine (140 mg/100mL) + Potassium acetate (128 mg/100mL) + Serine (147 mg/100mL) + Sodium Chloride (234 mg/100mL)Injection, solutionIntravenousHospira, Inc.2011-03-23Not applicableUs
Anti NauseaPhosphoric acid (21.5 mg/5mL) + D-glucose monohydrate (1.87 g/5mL) + Fructose (1.87 g/5mL)LiquidOralMedicine Shoppe International2008-02-062013-06-09Us
Anti NauseaPhosphoric acid (21.5 mg/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Fructose (1.87 g/5mL)LiquidOralKroger2000-10-042017-11-01Us
Anti NauseaPhosphoric acid (21.5 mg/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Fructose (1.87 g/5mL)LiquidOralH.E.B.1995-11-222017-09-08Us
Anti NauseaPhosphoric acid (21.5 mg/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Fructose (1.87 g/5mL)LiquidOralSafeway2007-07-30Not applicableUs
Anti NauseaPhosphoric acid (21.5 mg/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Fructose (1.87 g/5mL)LiquidOralRite Aid1996-06-122017-11-04Us
Anti NauseaPhosphoric acid (21.5 mg/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Fructose (1.87 g/5mL)LiquidOralMeijer Distribution1996-08-212017-11-01Us
Anti Nausea LiquidPhosphoric acid (21.5 mg/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Fructose (1.87 g/5mL)SolutionOralTopco Associates2018-05-14Not applicableUs
Butler Protect One Minute Apf Fluoride GelPhosphoric acid (1.31 %) + Hydrogen fluoride (0.17 %) + Sodium fluoride (1.23 %)GelTopicalJohn O. Butler Company2004-03-102009-07-09Canada
Childrens Emetrol CherryPhosphoric acid (21.5 mg/5mL) + Sucrose (3.74 g/5mL)SolutionOralWellSpring Pharmaceutical Corporation2012-11-052012-11-01Us
Categories
UNII
E4GA8884NN
CAS number
7664-38-2
Weight
Average: 97.9952
Monoisotopic: 97.976895096
Chemical Formula
H3O4P
InChI Key
NBIIXXVUZAFLBC-UHFFFAOYSA-N
InChI
InChI=1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4)
IUPAC Name
phosphoric acid
SMILES
OP(O)(O)=O

Pharmacology

Indication

Phosphoric acid is used in dentistry and orthodontics as an etching solution, to clean and roughen the surfaces of teeth where dental appliances or fillings will be placed.

Associated Therapies
Pharmacodynamics

Transport of phosphate from the gut lumen is an active, energy-dependent process that is modified by several factors. ... Vitamin D stimulates phosphate absorption, an effect reported to precede its action on calcium ion transport.

Mechanism of action

Phosphate supplementation of the diet of rodents has been shown to lead to reduction in the incidence of dental caries and different phosphates have different powers in reducing the cariogenic potential of the carbohydrates in a diet. Phosphate supplements seem to exert their cariostatic effect on the tooth surface either directly during eating or by excretion in the saliva.

Absorption

Ortho phosphate is absorbed from, and to a limited extent secreted into, the gastrointestinal tract.

Volume of distribution

Absorbed phosphoric acid is distributed widely in the body as phosphate. Increased serum phosphate concentrations have been reported rarely after phosphoric acid ingestion

Protein binding
Not Available
Metabolism
Not Available
Route of elimination

In adults, about two thirds of the ingested phosphate is absorbed, and that which is absorbed is almost entirely excreted into the urine.

Half life

In infants with normal renal function the serum half-life of phosphate following single oral or rectal overdose is 5-11 hours

Clearance

Absorbed phosphate is filtered at the glomerulus and partially reabsorbed, with phosphate clearance 80 per cent of creatinine clearance.

Toxicity

Man: LDLo, route unreported at 220mg/kg Rabbit: LD 50, Route: Skin, Reported dose: 2740 mg /kg, Effects: Behavioral : somnolence ( general depressed activity), Excitement Rat: LC50, Route: inhalation, Reported dose: >850 mg/m3/1h Rat: LD50, Route: oral, Reported dose: 1530 mg/kg, Effects: Kidney, ureter and bladder hematuria, Behavioral: somnolence (general depressed activity)

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
AcarboseAcarbose may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
AclidiniumAclidinium may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
AcrivastinePhosphoric acid may decrease the excretion rate of Acrivastine which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
AdefovirAdefovir may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
Food Interactions
Not Available

References

General References
  1. Pubchem [Link]
  2. ChemIDplus [Link]
  3. inChem [Link]
External Links
Human Metabolome Database
HMDB0002142
KEGG Compound
C00009
PubChem Compound
1004
PubChem Substance
347827839
ChemSpider
979
BindingDB
14671
ChEBI
26078
ChEMBL
CHEMBL1187
Wikipedia
Phosphoric_acid

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2RecruitingTreatmentMyelodysplastic Syndrome1
1, 2RecruitingTreatmentNeoplasms, Pancreatic1
Not AvailableCompletedTreatmentSelective Enamel Etching in Dental Restorations1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
LiquidDental
SolutionOral
Injection, solutionIntravenous
LiquidOral
GelDental
SolutionOral750 mg/1
GelTopical
LiquidDental; Topical
LiquidTopical
InjectionIntravenous
PasteDental
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-1ChemAxon
pKa (Strongest Acidic)1.8ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area77.76 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity14.65 m3·mol-1ChemAxon
Polarizability5.81 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MS (3 TMS)GC-MSsplash10-0002-0794000000-6c866e626b9356994d46
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0002-0394000000-3a469377821d88bd699f
GC-MS Spectrum - GC-MSGC-MSsplash10-0002-0794000000-6c866e626b9356994d46
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-000t-0972000000-2ddd7182426dbace5342
MS/MS Spectrum - Quattro_QQQ 10V, N/ALC-MS/MSsplash10-000t-9000000000-0e85f764ac98e8949759
MS/MS Spectrum - Quattro_QQQ 25V, N/ALC-MS/MSsplash10-001i-9000000000-869a362083996a0cec77
MS/MS Spectrum - Quattro_QQQ 40V, N/ALC-MS/MSsplash10-03di-9000000000-801101cccfd6c25271d4
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as non-metal phosphates. These are inorganic non-metallic compounds containing a phosphate as its largest oxoanion.
Kingdom
Inorganic compounds
Super Class
Homogeneous non-metal compounds
Class
Non-metal oxoanionic compounds
Sub Class
Non-metal phosphates
Direct Parent
Non-metal phosphates
Alternative Parents
Inorganic oxides
Substituents
Non-metal phosphate / Inorganic oxide
Molecular Framework
Not Available
External Descriptors
phosphoric acids (CHEBI:26078)

Drug created on November 30, 2015 12:10 / Updated on November 02, 2018 07:02